Aqua Bio Technology ASA: Primary insider notification

18 Feb 2026 17:40 CET

Reference is made to the Extraordinary General Meeting in Aqua Bio Technology
ASA ("ABTEC" or the "Company") on 16 February 2026 regarding the share capital
increase in connection with the reverse share split (50:1). The Company's
share capital shall be increased by NOK 3.30 through the issuance of 33 new
shares, each with a par value of NOK 0.10, to facilitate the reverse share
split. Kristian Flaten, CEO and CFO of Aqua Bio Technology ASA, has subscribed
for and been allocated 33 new shares at a price of NOK 0.25 per share.
Following this transaction, Flaten holds 33 shares in ABTEC. In addition,
Caprock AS, a company closely associated with Flaten, was allocated ABTEC
shares of NOK 300,000 (equal to 60,000 shares after the reverse share split)
in the private placement, to be registered after the reverse share split (ref
notice 13 February 2026).

This information is subject to the disclosure requirements pursuant to MAR
article 19.

Contacts
Kristian Flaten
CEO & CFO
Aqua Bio Technology ASA

Phone: +47 9509 2322
Email: kf@aquabiotech.no

About Us
Aqua Bio Technology ASA (ABTEC) is a technology and distribution group in
skincare and nonfood. The group has distribution towards B2C and B2B, and
offers freight, customs, and logistics services. The group also develops
sustainable biotechnology for use in skincare products. Aqua Bio Technology is
listed on Euronext Expand Oslo.

This notice is published by Kristian Flaten on the listed date and time.

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 17. The information was submitted for publication,
through the agency of the contact persons set out above, at 2026-02-18 17:40
CET.

More information:
Access the news on Oslo Bors NewsWeb site

666145_260218 ABTEC KRT1500 KF.pdf
666145_Aqua Bio Technology ASA- Primary insider notification.pdf